Insmed (NASDAQ:INSM) CEO William Lewis Sells 3,223 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 3,223 shares of Insmed stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $561,349.91. Following the sale, the chief executive officer owned 315,407 shares in the company, valued at $54,934,437.19. This represents a 1.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Price Performance

INSM stock opened at $170.27 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm has a 50 day moving average price of $190.31 and a 200-day moving average price of $151.37. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The firm has a market capitalization of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company’s revenue was up 52.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.27) earnings per share. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as “worth keeping an eye on,” which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
• Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
• Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in INSM. Royal Bank of Canada increased its stake in shares of Insmed by 33.2% in the 1st quarter. Royal Bank of Canada now owns 245,262 shares of the biopharmaceutical company’s stock worth $18,710,000 after purchasing an additional 61,190 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Insmed by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company’s stock valued at $8,364,000 after purchasing an additional 4,176 shares in the last quarter. Caxton Associates LLP bought a new stake in Insmed during the first quarter valued at about $441,000. Woodline Partners LP increased its position in Insmed by 53.3% in the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock worth $18,979,000 after buying an additional 86,540 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Insmed by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock worth $41,157,000 after buying an additional 52,637 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Redburn Partners set a $263.00 price objective on Insmed in a research report on Thursday, December 4th. Bank of America upped their price target on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Truist Financial started coverage on Insmed in a report on Friday, December 19th. They issued a “buy” rating and a $202.00 price objective for the company. The Goldman Sachs Group upped their target price on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.